OncLiveExpert Discusses Promise of Immunotherapy in TNBCOncLiveThe combination of immunotherapy and chemotherapy is showing promising response rates in certain patients with triple-negative breast cancer (TNBC), said ESO Umberto Veronesi Memorial Award… Continue reading
|
Prescribed Reading: CRISPR, Trump and FOURIER. Oh my!
BioPharma Dive Allergan is giving people one more reason to keep a close eye on CRISPR. The specialty pharma has teamed up with Editas Medicine to develop its eye-disease candidates, including the Cambridge biotech’s lead program in Leber Congenital Amaurosis … |
|
Computational Analysis of Immunotherapy Response Paints a Complex Picture
Immuno-Oncology News Using an advanced computational analysis may help scientists predict which patients are likely to respond to immunotherapy. But researchers — who hope a more integrated picture of the immune response might advance immunotherapy strategies — say … |
|
Computational Analysis of Immunotherapy Response Paints a Complex Picture
Immuno-Oncology News Using an advanced computational analysis may help scientists predict which patients are likely to respond to immunotherapy. But researchers — who hope a more integrated picture of the immune response might advance immunotherapy strategies — say … |
|
Cedars-Sinai, TransOmic Partner to Push AI-Driven CRISPR/Cas9 Design Tool to Market
GenomeWeb NEW YORK (GenomeWeb) – Genomic screening firm TransOmic has partnered with researchers from Cedars-Sinai Medical Institute and Cold Spring Harbor Laboratory to offer a promising but unproven artificial intelligence-driven CRISPR/Cas9 guide RNA … |